
Online consultations available nationwide, with home delivery across Japan.
International patients are very welcome. Customs certificates for returning travelers are also available.
- We use GLP-1 medications daily in our diabetes practice, giving us thorough knowledge of the drug’s properties, effects, and risks
- Comprehensive management of side effects (nausea, gastrointestinal symptoms). As internists, we can prescribe anti-nausea medication and additional treatments as needed
- Lifestyle disease values (blood sugar, blood pressure, lipids) monitored together
- Sleep apnea — a common obesity comorbidity — is also treated at this clinic
- We provide weight loss support with your overall health in mind, not just aesthetics
What Is Wegovy?
Wegovy (generic name: semaglutide 2.4mg) is a GLP-1 receptor agonist officially approved in Japan for obesity treatment in 2023. With once-weekly subcutaneous injections, the STEP 1 clinical trial (1,961 participants, 68 weeks) confirmed an average weight reduction of approximately 14.9%.
It acts directly on the brain’s satiety center to suppress appetite, physiologically creating a state where you feel less hungry and are satisfied with smaller portions — supporting weight loss without relying on willpower or strict dieting.
Who Is This Suitable For?
- Those seeking significant weight loss (10 kg or more)
- Those for whom other GLP-1 medications (Rybelsus, Ozempic, etc.) were insufficiently effective
- Those with BMI ≥ 27 with comorbidities such as hypertension, diabetes, or dyslipidemia
- Those with BMI ≥ 35
- Those who want to minimize effort with a once-weekly injection
- Those who have repeatedly tried conventional diets without achieving lasting results
Who Cannot Use This Medication?
- Those with a history of pancreatitis
- Those with a personal or family history of medullary thyroid carcinoma or MEN2
- Those who are pregnant, planning to become pregnant, or breastfeeding
- Those with a BMI below 18.5
- Those with severe gastrointestinal disorders
Common Side Effects
The most common side effects are gastrointestinal symptoms such as nausea, diarrhea, and constipation. Most resolve within 2–4 weeks after starting treatment. We can prescribe anti-nausea medication if needed.
| Side Effect | Frequency | Management |
|---|---|---|
| Nausea | ~20–30% | Small frequent meals; anti-nausea medication |
| Diarrhea | ~10–20% | Hydration; intestinal regulators |
| Constipation | ~10–20% | Hydration, fiber, laxatives |
| Headache / fatigue | ~5–10% | Observation |
| Acute pancreatitis (rare) | <0.1% | Seek immediate medical attention for severe upper/back pain |
Pricing (Tax included, shipping extra)
Shipping: ¥1,100–¥3,300 / No returns / Payment: credit card, bank transfer (Wise accepted), or cash
Consultation Flow
🏥 In-person visit (Sapporo, Chuo Ward)
-
Visit the clinic
No appointment necessary — walk in during clinic hours.
Advance booking also available → Booking page - Consultation
-
Payment & pickup
Pay on the day and take your medication home.
※ If you need a larger quantity (approx. 12 or more pens), please contact us in advance via the form to ensure availability.
🖥 Online consultation (nationwide)
-
Initial contact & booking
Please contact us via the form and book your consultation. -
Online consultation
Consultation by phone or video call. -
Payment
Credit card or bank transfer (Wise accepted) -
Delivery
After payment is confirmed, we will ship to your specified address.
Home, office, or hotel — nationwide delivery available. International shipping not available.
※ Customs certificates for returning travelers are available. ※ International shipping not available.
Frequently Asked Questions
- Q. Is health insurance accepted?
- When used for weight loss without a diagnosis of diabetes, treatment is self-pay (private). Patients diagnosed with diabetes may be eligible for insurance coverage.
- Q. How much weight can I expect to lose?
- In the STEP 1 clinical trial, an average of approximately 14.9% weight loss was confirmed. For a person weighing 80 kg, that equates to approximately 12 kg. Individual results may vary.
- Q. How does Wegovy compare to Mounjaro?
- Mounjaro (tirzepatide), with its dual GLP-1/GIP action, has shown greater weight reduction (avg. over 20%) than Wegovy. If you are looking for stronger weight loss, Mounjaro may be the better choice.
- Q. Will I regain weight if I stop?
- Appetite may return after stopping, leading to possible weight regain. Building healthy eating habits during treatment is key to preventing rebound.
- Q. Can international patients receive treatment?
- Yes. English support is available. We can also issue a medical certificate for customs declaration upon returning to your home country.
Book an online or in-person consultation
Book / Apply Here[Physician Explanation] Wegovy (Semaglutide): Effects, Side Effects, and STEP Trial Data
